Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

Omigapil maleate

EU orphan designation number: EU/3/08/540   
Active ingredient: Omigapil maleate
Indication: Treatment of congenital muscular dystrophy with collagen VI deficiency (Ullrich Syndrome and Bethlem Myopathy).
Sponsor: Santhera Pharmaceuticals (Deutschland) GmbH
Wallbrunnstrasse 24, D-79539 Lörrach, Deutschland

   Public summary of scientific opinion    

 

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
14/05/2008 Centralised Orphan - Designation EMEA/OD/104/07 (2008)1900 of 08/05/2008